title: Ambulatory monitoring predicts development of drug-treated hypertension in subjects with high normal blood pressure.
abstract: BACKGROUND
  High normal blood pressure (HNBP), i.e. blood pressure (BP) > or = 130/85 mmHg and <140/90 mmHg, is an important predictor of progression to established hypertension.
  
  
  METHODS
  The purpose of this retrospective study was the evaluation of the predictive value of ambulatory blood pressure monitoring (ABPM) for the development of drug-treated hypertension in subjects with HNBP and other risk factors.
  
  
  METHODS
  We studied 127 subjects (69 M, 58 F, age 50 +/- 14 years): 59 subjects had normal BP (NBP: < 130/85 mmHg), 68 subjects had systolic and/or diastolic HNBP. All the subjects underwent ABPM. There were 21/68 (30.9%) subjects in the HNBP group vs. 1/59 (1.7%) in the NBP group with an elevated (>135/85 mmHg) daytime ambulatory blood pressure (ABP) (p < 0.01).
  
  
  RESULTS
  After an average follow-up of 103 +/- 28 months, 27 subjects (39.7%) in the HNBP group and 4 subjects (6.8%) in the NBP group developed drug-treated hypertension (p < 0.01). An elevated daytime ABP correctly predicted development of drug-treated hypertension in 17/21 subjects (81%) of the HNBP group and in the only subject of the NBP group. Development of drug-treated hypertension was associated with higher office and ambulatory BP (p < 0.01) and pulse pressures (p < 0.05), longer follow-up (p < 0.05) and higher prevalence of hypercholesterolaemia and smoking (p < 0.01).
  
  
  CONCLUSIONS
  We conclude that ABPM correctly predicts development of drug-treated hypertension in most subjects who were identified early as having a daytime mean ABP >135/85 mmHg. ABPM appears to be a useful clinical tool in the early diagnosis of hypertension in subjects with metabolic risk factors and smoking.
authors.affiliation: Department of Cardiovascular and Respiratory Sciences, La Sapienza University of Rome, Rome, Italy. gpann@libero.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pannarale
authors.forename: Carlo
authors.initials: C
authors.lastname: Gaudio
authors.forename: Francesca
authors.initials: F
authors.lastname: Mirabelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Monti
authors.forename: Silvia
authors.initials: S
authors.lastname: Franchitto
authors.forename: Sara
authors.initials: S
authors.lastname: Di Michele
authors.forename: Paolo Emilio
authors.initials: PE
authors.lastname: Puddu
authors.forename: Francesco
authors.initials: F
authors.lastname: Fedele
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018660:Blood Pressure Monitoring, Ambulatory; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D006973:Hypertension / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D000959:Antihypertensive Agents